Phase 2b (Top-line Data)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Matrix-M Adjuvant in Malaria Vaccine - Top-line Data
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
5-11-2020 Re: Matrix-M Partnership (Novavax Reports First Quarter 2020 Financial Results)
2017: Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with matrix-m™. Vaccine, 35(45), 6208-6217.
MECHANISM OF ACTION/RATIONALE
Matrix-M™ is Novavax’ next-generation, patented saponin-based adjuvant, powered by a new formulation that provides a potent adjuvant effect and is well-tolerated. Saponins are steroid or triterpenoid glycosides, which occur in many plant species. In Matrix-M, purified saponin fractions are mixed with synthetic cholesterol and a phospholipid to form stable particles than can be readily formulated with a variety of vaccine antigens. Saponin-based adjuvants act in part by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in the local lymph nodes. Thus, Matrix-M™ induces both a cell-mediated and an antibody mediated immune response, which we expect will be important in developing future vaccines. Matrix-M™ also increases the opportunity for an immune reaction with longer duration, which can reduce the number of vaccinations needed to gain optimal protection. (See details)
Updated by HC
Novavax, NVAX, Matrix-M, Malaria Vaccine
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post